Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01471353 · ClinicalTrials.gov registry record · Phase 2
Sorafenib Plus Capecitabine (SorCape) in Previously Treated Metastatic Colorectal Cancer
A Phase 2 study, sponsored by University of Florida.
- Completed
- Registry status
- Phase 2
- Development phase
- 43
- Enrollment target
NCT01471353 is a Phase 2 study that has completed, run by University of Florida. The registered enrollment target is 43 participants.
The verdict
NCT01471353, a Phase 2 study, has completed, sponsored by University of Florida.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 43 participants
- Enrollment target
Study Summary
Combining Sorafenib with standard cytotoxic fluoropyrimidine therapy for advanced colorectal cancer may provide clinical benefit when no other treatment remains.
Interventions
- DRUG Sorafenib Plus Capecitabine (SorCape)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2011-11 |
| Est. Completion | 2017-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01471353
The ClinicalTrials.gov registry entry for NCT01471353 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Sorafenib Plus Capecitabine (SorCape) is the first listed.
NCT01471353 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01471353 about?
NCT01471353 is a clinical study titled "Sorafenib Plus Capecitabine (SorCape) in Previously Treated Metastatic Colorectal Cancer". Combining Sorafenib with standard cytotoxic fluoropyrimidine therapy for advanced colorectal cancer may provide clinical benefit when no other treatment remains.
What is the current status of trial NCT01471353?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 43 participants. The study started on 2011-11. Estimated completion is 2017-05.
What interventions are being tested in trial NCT01471353?
The interventions under investigation include: Sorafenib Plus Capecitabine (SorCape) (DRUG).
Who is sponsoring clinical trial NCT01471353?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.